162 related articles for article (PubMed ID: 8401250)
1. Roferon-A (interferon alpha 2a) combined with Tigason (etretinate) for treatment of cutaneous T cell lymphomas.
Dréno B
Stem Cells; 1993 Jul; 11(4):269-75. PubMed ID: 8401250
[TBL] [Abstract][Full Text] [Related]
2. Roferon-A in combination with Tigason in cutaneous T-cell lymphomas.
Dreno B; Celerier P; Litoux P
Acta Haematol; 1993; 89 Suppl 1():28-32. PubMed ID: 8475670
[TBL] [Abstract][Full Text] [Related]
3. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate.
Dréno B; Claudy A; Meynadier J; Verret JL; Souteyrand P; Ortonne JP; Kalis B; Godefroy WY; Beerblock K; Thill L
Br J Dermatol; 1991 Nov; 125(5):456-9. PubMed ID: 1751352
[TBL] [Abstract][Full Text] [Related]
4. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
5. Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma.
Zachariae H; Thestrup-Pedersen K
J Invest Dermatol; 1990 Dec; 95(6 Suppl):206S-208S. PubMed ID: 2258637
[TBL] [Abstract][Full Text] [Related]
6. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
7. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II.
Stadler R; Otte HG; Luger T; Henz BM; Kühl P; Zwingers T; Sterry W
Blood; 1998 Nov; 92(10):3578-81. PubMed ID: 9808550
[TBL] [Abstract][Full Text] [Related]
8. In vitro induction of basal keratinocyte MY7 antigen expression in cutaneous T-cell lymphoma is associated with response to interferon-alfa therapy.
Celerier P; Fleischmann M; Basset-Seguin N; Thill L; Bureau B; Litoux P; Dréno B
Arch Dermatol; 1993 Sep; 129(9):1136-40. PubMed ID: 8103318
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
10. [Interferon-alpha in cutaneous T-cell lymphoma].
Knobler R
Wien Med Wochenschr; 1993; 143(16-17):435-7. PubMed ID: 8273368
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha (INF-alpha) and etretinate in the treatment of mycosis fungoides.
Torii H; Kaneko T; Matsuyama T; Nakanishi H; Harada S
J Dermatol; 1994 Oct; 21(10):767-70. PubMed ID: 7798436
[TBL] [Abstract][Full Text] [Related]
12. Induction of myelo-monocytic My7 antigen (CD13) expression by interferon-alpha in basal cells of cutaneous T-cell lymphomas.
Dreno B; Fleischmann M; Valard S; Godefroy W; Bureau B; Stadler JF; Litoux P
Br J Dermatol; 1992 Apr; 126(4):320-3. PubMed ID: 1349233
[TBL] [Abstract][Full Text] [Related]
13. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma.
Marolleau JP; Baccard M; Flageul B; Rybojad M; Laroche L; Vérola O; Brandely M; Morel P; Gisselbrecht C
Arch Dermatol; 1995 May; 131(5):574-9. PubMed ID: 7741545
[TBL] [Abstract][Full Text] [Related]
14. Correlation of clinical responses with immunologic and morphologic characteristics in patients with cutaneous T-cell lymphoma treated with interferon alfa-2a.
Springer EA; Kuzel TM; Variakojis D; Kaul K; Rosen ST; Roenigk HH
J Am Acad Dermatol; 1993 Jul; 29(1):42-6. PubMed ID: 7686188
[TBL] [Abstract][Full Text] [Related]
15. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
Bosisio FM; Cerroni L
Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852
[TBL] [Abstract][Full Text] [Related]
16. Systemic treatment for cutaneous lymphomas.
Mielke V; Staib G; Sterry W
Recent Results Cancer Res; 1995; 139():403-8. PubMed ID: 7597307
[TBL] [Abstract][Full Text] [Related]
17. Extracorporeal photopheresis and multimodality immunomodulatory therapy in the treatment of cutaneous T-cell lymphoma.
Richardson SK; McGinnis KS; Shapiro M; Lehrer MS; Kim EJ; Vittorio CC; Junkins Hopkins JM; Rook AH
J Cutan Med Surg; 2003; 7(4 Suppl):8-12. PubMed ID: 12958701
[No Abstract] [Full Text] [Related]
18. High dose etretinate and interferon-alpha--a phase I study in squamous cell carcinomas and transitional cell carcinomas.
Roth AD; Morant R; Alberto P
Acta Oncol; 1999; 38(5):613-7. PubMed ID: 10427950
[TBL] [Abstract][Full Text] [Related]
19. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma.
Roenigk HH; Kuzel TM; Skoutelis AP; Springer E; Yu G; Caro W; Gilyon K; Variakojis D; Kaul K; Bunn PA
J Invest Dermatol; 1990 Dec; 95(6 Suppl):198S-205S. PubMed ID: 2258636
[TBL] [Abstract][Full Text] [Related]
20. Intramuscular low dose alpha-2B interferon and etretinate for treatment of mycosis fungoides.
Altomare GF; Capella GL; Pigatto PD; Finzi AF
Int J Dermatol; 1993 Feb; 32(2):138-41. PubMed ID: 8440560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
